UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
Information Required in Proxy Statement
Schedule 14a Information
Proxy Statement Pursuant to Section 14(a) of The Securities
Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒
Filed by a Party other than the
Registrant ☐
Check the appropriate box:
☐ Preliminary
Proxy Statement
☐ Confidential,
for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
☐ Definitive
Proxy Statement
☒ Definitive
Additional Materials
☐ Soliciting
Material Under Rule 14a-12
|
|
|
|
SUMMIT THERAPEUTICS INC. |
|
(Name of Registrant as Specified in Its Charter) |
|
|
(Name of Persons(s) Filing Proxy Statement, if Other Than the
Registrant) |
Payment of Filing Fee (Check the appropriate box):
☒ No
fee required.
☐ Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and
0-11.
(1) Title of each class of securities to
which transaction applies:
(2) Aggregate number of securities to which
transaction applies:
(3) Per unit price or other underlying value
of transaction computed pursuant to Exchange Act Rule 0-11 (set
forth the amount on which the filing fee is calculated and state
how it was determined):
(4) Proposed maximum aggregate value of
transaction:
(5) Total fee paid:
☐ Fee
paid previously with preliminary materials:
☐ Check
box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by
registration statement number, or the form or schedule and the date
of its filing.
(1) Amount previously paid:
(2) Form, Schedule or Registration Statement
No.:
(3) Filing Party:
(4) Date Filed:
SUMMIT THERAPEUTICS INC.
2882 Sand Hill Road, Suite 106
Menlo Park, California 94025
ADDITIONAL INFORMATION REGARDING THE ANNUAL MEETING OF SHAREHOLDERS
ORIGINALLY SCHEDULED FOR JUNE 15, 2022
The following Notice of Change of Date of Annual Meeting of
Shareholders relates to and supplements the 2022 Notice of Annual
Meeting of Shareholders and Proxy Statement (the “Proxy Statement”)
of Summit Therapeutics Inc. (the “Company”), filed with the
Securities and Exchange Commission on April 29, 2022 which was
subsequently mailed or made available to the Company’s shareholders
in connection with the solicitation of proxies by the Company for
use at the 2022 annual meeting of shareholders (the “Annual
Meeting”) originally scheduled for Wednesday, June 15, 2022 at 1:00
p.m., Eastern Time.
On June 3, 2022, the Company issued the following press release
related to a change in date of the Annual Meeting. As described
below, the Annual Meeting will now be held on Thursday, June 16,
2022 at 1:00 p.m., Eastern Time in a virtual-only meeting format.
As there will not be a physical location, shareholders will not be
able to vote their shares in person at the Annual Meeting.
Shareholders will instead be able to vote their shares by
submitting a proxy in advance of the Annual Meeting using one of
the methods described in the proxy materials for the Annual
Meeting, or by attending the Annual Meeting virtually following the
instructions outlined in the Notice of Change of Date of Annual
Meeting of Shareholders.
Except as specifically stated in this supplement, the information
set forth in the Proxy Statement remains unchanged.
THE NOTICE SHOULD BE READ IN CONJUNCTION WITH THE PROXY
STATEMENT.
Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting
Rescheduled to June 16, 2022, at 1:00pm Eastern Time
Menlo Park, CA, June 03, 2022 (GLOBE NEWSWIRE) -- Summit
Therapeutics Inc. (NASDAQ: SMMT) invites our shareholders and other
interested parties to attend our Company’s Annual Shareholders’
Meeting, which will now be held virtually on Thursday, June 16,
2022, at 1:00 pm Eastern Time, one day later than previously
planned. We are providing notice of the change in advance to allow
for accommodation for attendance. We look forward to your
attendance at this meeting.
As a reminder, in order to vote and/or submit questions during our
Annual Shareholders’ Meeting, attendees must log into the virtual
meeting with their unique control number provided with their 2022
Summit Therapeutics proxy statement and annual meeting information.
This information was provided to shareholders as of our record date
of April 26, 2022, either through a physical mailing or through
shareholders’ brokerage firms in which their shares are
held.
A link to the event can be found here:
www.virtualshareholdermeeting.com/SMMT2022.
Summit Therapeutics’ Mission Statement
To build a viable, long-lasting health care organization that
assumes full responsibility for designing, developing, trial
execution and enrollment, regulatory submission and approval, and
successful commercialization of patient, physician, caregiver, and
societal-friendly medicinal therapy intended to: improve quality of
life, increase potential duration of life, and resolve serious
medical healthcare needs. To identify and control promising product
candidates based on exceptional scientific development and
administrational expertise, develop our products in a rapid,
cost-efficient manner, and to engage commercialization and/or
development partners when appropriate.
We accomplish this by building a team of world class professional
scientists and business administrators that apply their experience
and knowledge to this mission. Team Summit exists to pose,
strategize, and execute a path forward in medicinal therapeutic
health care that places Summit in a well-deserved, top market
share, leadership position. Team Summit assumes full responsibility
for stimulating continuous expansion of knowledge, ability,
capability, and well-being for all involved stakeholders and
highly-valued shareholders.
About Summit Therapeutics
Summit was founded in 2003 and our shares are listed on the Nasdaq
Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park,
California, and we have additional offices in Oxford, UK, and
Cambridge, UK.
For more information, please visit
https://www.summittxinc.com
and follow us on Twitter @summitplc.
Contact Summit Investor Relations:
Dave Gancarz
Head of Stakeholder Relations & Corporate Strategy
david.gancarz@summitplc.com
General Inquiries:
investors@summitplc.com
Summit Forward-looking Statements
Any statements in this press release about the Company’s future
expectations, plans and prospects, including but not limited to,
statements about the clinical and preclinical development of the
Company’s product candidates, the therapeutic potential of the
Company’s product candidates, the potential commercialization of
the Company’s product candidates, the timing of initiation,
completion and availability of data from clinical trials, the
potential submission of applications for marketing approvals, the
impact of the COVID-19 pandemic on the Company’s operations and
clinical trials, potential acquisitions and other statements
containing the words "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "should," "target," "would," and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including the results of our evaluation of the underlying
data in connection with the topline results of our Phase III
Ri-CoDIFy study evaluating ridinilazole, the outcome of discussions
with regulatory authorities, including the Food and Drug
Administration, the uncertainties inherent in the initiation of
future clinical trials, availability and timing of data from
ongoing and future clinical trials, the results of such trials, and
their success, and global public health crises, including the
coronavirus COVID-19 outbreak, that may affect timing and status of
our clinical trials and operations, whether preliminary results
from a clinical trial will be predictive of the final results of
that trial or whether results of early clinical trials or
preclinical studies will be indicative of the results of later
clinical trials, whether business development opportunities to
expand the Company’s pipeline of drug candidates, including without
limitation, through potential acquisitions of, and/or
collaborations with, other entities occur, expectations for
regulatory approvals, laws and regulations affecting government
contracts and funding awards, availability of funding sufficient
for the Company’s foreseeable and unforeseeable operating expenses
and capital expenditure requirements and other factors discussed in
the "Risk Factors" section of filings that the Company makes with
the Securities and Exchange Commission. Any change to our ongoing
trials could cause delays, affect our future expenses, and add
uncertainty to our commercialization efforts, as well as to affect
the likelihood of the successful completion of clinical development
of ridinilazole. Accordingly, readers should not place undue
reliance on forward-looking statements or information. In addition,
any forward-looking statements included in this press release
represent the Company’s views only as of the date of this release
and should not be relied upon as representing the Company’s views
as of any subsequent date. The Company specifically disclaims any
obligation to update any forward-looking statements included in
this press release.
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Feb 2023 to Mar 2023
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Mar 2022 to Mar 2023
